Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vepdegestrant PK DDI with Carbamazepine
NCT06005688Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2023
- Primary completion
- Oct 2023
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vepdegestrant in breast cancer, sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration at 144 hours and Area Under the Curve From Time Zero to Extrapolated Infinite Time at 144 hours. Started Aug 2023; status: completed.
02
Drugs
vepdegestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06005688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06005688.